Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

301 results about "Anticoagulation Agents" patented technology

Medical Definition of Anticoagulant agent. Anticoagulant agent: A medication used to prevent the formation of blood clots and to maintain open blood vessels. Anticoagulants are called blood "thinners," but they do not thin the blood, they only prevent or reduce clots, or thrombi. Anticoagulants have various uses.

Abnormal blood sampling test data evaluation processing method and system of blood sampling system

The invention provides an abnormal blood sampling inspection data evaluation processing method and system of a blood sampling system. Wherein the diffusion track dynamic state of an anticoagulant-blood contact surface in a blood sampling tube is tracked in real time, dielectric response waveform distortion characteristics on the two sides are synchronously collected through a capacitance sensor array, and diffusion form parameters are generated; curvature sudden change is analyzed to trigger an acoustic fluid device to modulate audio frequency and flow velocity, and a composite disturbance field is formed; performing capacitance axial scanning on the disturbed mixed fluid, extracting phase angle offset and gradient abrupt change point coordinates, and constructing a dielectric anomaly three-dimensional map; matching a standard dielectric model, positioning a coordinate set of a concentration gradient imbalance area and a coordinate set of an eddy current attenuation area, and generating an anticoagulant abnormal index and a mixed defect matrix in combination with phase angle offset difference; and establishing a data anomaly degree evaluation function based on the anomaly index and the defect matrix, dynamically associating a clinical error threshold, and outputting a test evaluation result. According to the invention, anticoagulant diffusion can be monitored in real time, and the mixing quality error can be accurately evaluated.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Sample pretreatment automation method for flow detection

The invention provides a sample pretreatment automation method for flow cytometry, and belongs to the technical field of sample pretreatment for flow cytometry. A biological sample to be detected is collected and placed in a collection tube containing an EDTA-K2 anticoagulant for pretreatment; an automatic pipetting system is used for carrying out incubation reaction on an anticoagulant whole blood sample and an intelligent matching fluorescence labeling antibody mixed solution, and a double-layer game optimization verification system is used for verifying the rationality of an antibody adding proportion and reaction condition parameters; carrying out fluorescence characteristic readability index prediction on the incubated cell suspension by adopting an intelligent dilution parameter regulator model, dynamically adjusting hemolysis parameters and suspension conditions, and adding 1 * hemolysin working solution by using an automatic liquid adding device to carry out hemolysis treatment so as to finish pretreatment; the technical problems that in the pretreatment process of flow cytometry detection samples, parameters are often based on artificial experience, and the reproducibility and standardization degree of detection results are insufficient are solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant

ActiveUS12178436B2TourniquetsTime to hemostasisBody weight
Disclosed are methods and devices for obtaining patent hemostasis of the radial artery by compressing the uninstrumented ulnar artery to increase radial artery flow. The device comprises a band having an inflatable bladder for applying blunt pressure to the ulnar artery. The method comprises applying a pressure to the homolateral ulnar artery and applying a pressure to the radial artery at the access site to obtain hemostasis at the access site. The method further comprises administering an anticoagulant to a patient at a dose ranging from about 20 units per kg of body weight to about 30 units per kg of body weight.
Owner:VASOINNOVATIONS INC

Non-invasive urinary system urine tumor fluorescence developing reagent and use method thereof

The invention discloses a non-invasive urinary system urine tumor fluorescence developing reagent and a use method thereof. The fluorescence developing reagent is composed of fluorescein, a stabilizer, an anti-bleaching agent, an anticoagulant and a buffer solution, the fluorescent color developing reagent comprises the following components in percentage by weight: 0.1%-2% of sodium chloride, 0.1%-5% of glycerol, 0.01%-1% of ethylenediamine tetraacetic acid or sodium salt or potassium salt thereof, 0.001%-0.01% of fluorescein, 1-10 mmol / L of an anti-bleaching agent and 0.01-1 mol / L of a buffer solution. After fluorescein staining, cell nucleuses show yellow green or yellow fluorescence, cytoplasm shows orange or flame fluorescence due to existence of more RNA, changes of cell morphology and chemical fluorescence can be observed at the same time according to the characteristic that cell morphology and chemical fluorescence are combined, and the defect that traditional Pasteur cytology staining is insufficient in sensitivity and specificity is overcome.
Owner:HANGZHOU HUIDEKANG MEDICAL TECHNOLOGY CO LTD

Method for estimating factor of blood coagulation abnormality

PCT designated stage expiredWO2025075088A1Biological testingBlood specimenHematological test
Provided is a method for estimating a factor causing an abnormality in coagulation of a blood sample. In the method, 1) a parameter Ps relating to a coagulation reaction in a sample S and a parameter Pm relating to a coagulation reaction in a sample M are calculated, 2) an estimation as to whether the sample S is coagulation-factor-inhibitor-positive is carried out on the basis of Ps, and 3) a sample S that is not estimated to be coagulation-factor-inhibitor-positive in 2) is estimated to be lupus-anticoagulant-positive or coagulation-factor-deficient on the basis of Pm or on the basis of Ps and Pm. The sample S is a test blood sample having an extended coagulation time, the sample M is a mixed sample of the sample S and a sample N, and the sample N is a normal blood sample. Ps is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample S reaches a prescribed value, and Pm is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample M reaches a prescribed value.
Owner:SEKISUI MEDICAL CO LTD +1

Blood sampling heat preservation device for animal epidemic disease detection

The invention discloses a blood sampling heat preservation device for animal epidemic disease detection, which comprises a storage box, a heat preservation cavity is arranged in the storage box, a plurality of groups of heating rods are arranged in the heat preservation cavity, an annular conveying belt is arranged in the heat preservation cavity, a plurality of groups of bottle placing seats which are arrayed at equal intervals are arranged on the annular conveying belt, and the bottle placing seats are rotatably connected with the annular conveying belt; sampling bottles are placed in the multiple sets of bottle placing bases, taking and placing holes matched with the sampling bottles are formed in the upper portion of the heat preservation cavity, and sealing plates hinged to the inner walls of the taking and placing holes are installed in the taking and placing holes. The device has the beneficial effects that a second gear at the power output end of a motor is matched with a first gear to drive a bottle placement seat to rotate so as to drive a sampling bottle to rotate, so that sampled blood in the sampling bottle is fully mixed with an anticoagulant, and meanwhile, the sampling bottle is in a heat preservation environment in a heat preservation cavity in the whole process of rotation; blood in the sampling bottle is prevented from going bad when being cooled to influence a subsequent detection result.
Owner:LUOYANG BOTAI TESTING TECH CO LTD

Multi-board division cooperative control system based on blood purification equipment

The invention relates to a multi-board division cooperative control system based on blood purification equipment, which comprises a man-machine interaction unit, a liquid balance unit, a blood loop unit, a blood anticoagulation unit and a power supply unit, each unit is an operation unit with independent hardware, is provided with an independent PCB (Printed Circuit Board) and an independent DCDC (Direct Current-Direct Current) circuit, and performs data interaction through a custom protocol on a CAN (Controller Area Network) bus. The man-machine interaction unit receives user input and displays an equipment state; the liquid balance unit adjusts liquid input and output in the purification process; the blood loop unit is used for establishing and maintaining in-vitro blood circulation; the blood anticoagulation unit controls the injection of an anticoagulant; and the power supply unit provides power support for each module. Each unit operates independently, and only a single unit needs to be replaced when a fault occurs, so that the reliability and the maintenance efficiency of the system are improved. According to the system, modularization and efficient cooperation are achieved through distributed design, and it is ensured that equipment operates stably and safely in the blood purification process.
Owner:HUNAN UNIV

Platelet-derived mitochondria-containing extracellular vesicles for use in the treatment of ocular disorders - Patent Application 20070233633

Platelet-derived extracellular vesicles (PEVs) containing mitochondria are used in treating ocular disorders or symptoms of ocular disorders. The PEVs are collected by obtaining blood from one or more donors, adding an anticoagulant and a buffer to the blood to form a mixture, separating the mixture into a supernatant and platelet-rich plasma (PRP), collecting the PRP, stimulating the collected PRP to displace the extracellular vesicles from the platelets in the PRP, and collecting the extracellular vesicles as PEVs.
Owner:MITRIX BIO INC

Platelet derivative compositions in the form of a powder

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
Owner:CELLPHIRE INC

Preparation method and application of autologous fibrin glue

PendingCN120789326AFibrinogenSurgical adhesivesCa2 activationFibrin glue
The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.
Owner:SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE

Autologous platelet-containing plasma gel as well as preparation method and application thereof

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.
Owner:揭阳市人民医院

Hemodialysis membrane with self-anticoagulation function and preparation method thereof

The invention discloses a hemodialysis membrane with a self-anticoagulation function and a preparation method of the hemodialysis membrane. The hemodialysis membrane with the self-anticoagulation function is obtained by modifying natural polymer fibrin, polydopamine and a sulfonic acid type polymer solution. The hemodialysis membrane is any one or more of a polysulfone membrane, a polyether sulfone membrane, a polyvinylidene fluoride membrane, a polymethyl methacrylate membrane, a polyacrylonitrile membrane, a polyamide membrane, a polyvinyl alcohol membrane, a cellulose acetate membrane and a polypropylene membrane. The invention is used for treating acute and chronic kidney diseases, has good biocompatibility, and shows good blood compatibility in the aspects of inhibiting protein adsorption, platelet adsorption and red blood cell adsorption, reducing hemolysis rate, prolonging blood coagulation time and the like. And the risk of thrombosis caused by improper use of an anticoagulant in a continuous anticoagulation treatment process can be effectively avoided, and the living quality and the survival time of a hemodialysis patient are effectively improved and prolonged.
Owner:成都欧赛医疗器械有限公司

Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant

ActiveUS20250072898A1TourniquetsBody weightArteria ulnaris
Disclosed are methods and devices for obtaining patent hemostasis of the radial artery by compressing the uninstrumented ulnar artery to increase radial artery flow. The device comprises a band having an inflatable bladder for applying blunt pressure to the ulnar artery. The method comprises applying a pressure to the homolateral ulnar artery and applying a pressure to the radial artery at the access site to obtain hemostasis at the access site. The method further comprises administering an anticoagulant to a patient at a dose ranging from about 20 units per kg of body weight to about 30 units per kg of body weight.
Owner:VASOINNOVATIONS INC

System and method for collecting plasma

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.
Owner:HAEMONETICS CORP

System and method for collecting plasma

A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume. The target plasma collection volume is based on the donor plasma volume and a target percentage of plasma. The method then withdraws blood from the donor through a line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate the volume of pure plasma collected within the plasma collection container, and continue processing / collecting until the calculated volume of pure plasma equals the target plasma collection volume.
Owner:HAEMONETICS CORP

High-precision detection method for abnormal plasma cells

The invention discloses a high-precision detection method of abnormal plasma cells, which comprises the following steps: preparing a film, immediately and uniformly mixing the extracted marrow fluid with an anticoagulant, sequentially diluting and centrifuging the marrow, then collecting a leukocyte layer, washing with a fluid medium RPMI 1640 / 5% FBS for at least one time, then counting the cells, adjusting the cell concentration to 1 * 10 < 6 > / ml, adding 100 [mu] l of the cell suspension into a funnel of a cell centrifugal smear device, centrifuging at room temperature for 1000 revolutions, continuing for 5 minutes, and preserving a slide filled with the cell suspension; the preparation of FISH cells comprises the following steps: firstly, preparing and pretreating a 90% formamide / 2 * SSC solution; according to the method, the accuracy and the efficiency of abnormal plasma cell detection are improved by combining an intelligent AI recognition model and a fluorescence in situ hybridization (FISH) technology. The application of the intelligent AI recognition model can reduce personal errors and improve the recognition capability of fluorescence signals, thereby improving the accuracy of detection results.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)

Compositions and uses thereof for stabilization of blood sample components

PCT designated stage expiredWO2024192232A9Pharmaceutical delivery mechanismDead animal preservationBlood specimenCitrate anticoagulation
Provided herein are compositions comprising (1) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), a calcium channel blocker, and a sodium channel blocker and (2) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), and a sodium channel blocker, and uses of such compositions for stabilizing components in a blood sample.
Owner:STRECK LLC

Therapeutic APAC Molecule Comprising Heparin Conjugated to a Plasma Protein

The invention relates to an anti-thrombotic molecule having both antiplatelet and anticoagulant (APAC) activity; its use as a medicament; its selective configuration and use as an anticoagulant and platelet inhibitor, or its selective configuration and use predominantly as either an anticoagulant or a platelet inhibitor; and a method for its production.
Owner:APLAGON

Blood component single sampling equipment capable of monitoring in real time

The invention discloses blood component single sampling equipment capable of monitoring in real time in the field of blood treatment equipment. The equipment comprises a blood sampling module, a centrifugal separation module, a component collection module and an anticoagulant conveying module, and further integrates a multi-dimensional real-time monitoring system and a closed-loop self-adaptive regulation and control module. The multi-dimensional real-time monitoring system comprises an online micro-fluidic component detection unit, a physiological parameter monitoring unit and an equipment operation monitoring unit, can realize real-time online detection of blood component purity, cell activity and pollutant residue in the separation process, and synchronously monitors circulation physiological parameters of a blood donor and an equipment operation state at the same time; the closed-loop self-adaptive regulation and control module can dynamically adjust parameters such as the centrifugal rotating speed, the fluid pump speed and the anticoagulant ratio according to real-time monitoring data, and precise closed-loop control over the separation process is achieved. The quality stability of blood single-sampling components can be remarkably improved, meanwhile, the operation risk is greatly reduced, and the method is suitable for clinical blood component single-sampling and preparation scenes.
Owner:CHONGQING TRADITIONAL CHINESE MEDICINE HOSPITAL

Processing method of pigeon blood bean curd

The invention discloses a processing method of pigeon blood tofu. The content of protein peptide and the absorbable utilization degree of protein in a pigeon blood tofu finished product are improved. The method comprises the following steps: (1) anticoagulant treatment: adding an anticoagulant into fresh pigeon blood, and uniformly mixing; (2) extracting the pigeon blood protein: adjusting the pH value of the anticoagulant pigeon blood to the isoelectric point of the pigeon blood protein, centrifuging, and collecting the precipitate to obtain the pigeon blood protein; (3) pre-digestion treatment: carrying out enzymolysis pre-digestion treatment on the pigeon blood protein by using pepsin and trypsin in sequence; (4) making pigeon blood bean curds: adding guar gum, carrageenan, calcium chloride and water into the pre-digested pigeon blood protein, performing reflux treatment by using a colloid mill, and then heating gel to obtain the pigeon blood bean curds; (5) inoculating and fermenting: inoculating debaryomyces hansenii suspension into the pigeon blood tofu, and fermenting; and sterilizing the fermented pigeon blood tofu with steam, and cooling to obtain the pigeon blood tofu product.
Owner:SERICULTURAL &AGRI FOOD RESEARCH INSTITUTE GUANGDONG ACADEMY OF AGRICULTURAL SCIENCES +3

Method for extracting sika deer blood polypeptide through microwave-assisted enzyme method and application of sika deer blood polypeptide in anti-fatigue food

The invention relates to an enzymolysis technology and a microwave-assisted extraction technology in a bioengineering technology, in particular to a method for extracting sika deer blood polypeptide through a microwave-assisted enzyme method and application of the sika deer blood polypeptide in anti-fatigue food. Treating the deer blood by using a composite anticoagulant containing sodium citrate, centrifuging, and freezing and thawing to obtain a lysate; carrying out microwave-assisted malic acid acidification, carrying out staged enzymolysis by using a compound enzyme composed of bromelain according to a ratio of 4: 3: 2, and introducing carbon dioxide to control the pH value; performing enzyme deactivation and centrifugal ultrafiltration to obtain a crude product, purifying the crude product through an ion exchange column and a gel column, and performing Maillard reaction modification with chitosan oligosaccharide; and finally preparing the anti-fatigue food with maltodextrin as an auxiliary material. According to the method, the yield of the sika deer blood polypeptide is greatly improved, the proportion of high-activity small molecule peptide is extremely high, the stability and bioavailability of the modified polypeptide are remarkably improved, and the bitter taste is reduced; the efficacy of the prepared anti-fatigue food is superior to that of similar products, and high-value utilization of deer blood resources is promoted.
Owner:JILIN ZHENGHE BIOTECHNOLOGY CO LTD

Medical systems and storage media

ActiveCN115025310BReduce anticoagulation safety risksSimplify anticoagulation control stepsOther blood circulation devicesMedical devicesHematological testAnti coagulation
The present application discloses a medical system and a storage medium, the medical system includes: a memory and a processor, the memory is used to store a computer program; the processor is used to execute the computer program and implement the following anticoagulation control method: when the user's operation indicating blood purification is detected, the blood circuit is controlled to transmit blood for blood purification; the actual flow rate of the blood in the blood circuit is detected, when the actual flow rate meets the first condition, the second flow rate of the anticoagulation branch is determined according to the actual flow rate, and a first control instruction is issued to the infusion pump, the first condition is: the difference between the actual flow rate and the first flow rate is greater than the preset error value; when the infusion pump receives the first control instruction, the infusion pump controls the anticoagulation branch according to the first control instruction to output the anticoagulant to the blood circuit at the second flow rate. The present application can automatically match the blood purification equipment and the infusion pump for linkage control to ensure the safety of the patient during the blood purification process.
Owner:ZHUHAI MEIRUIHUA MEDICAL TECH

Anticoagulant compositions comprising Anti-platelet and Anti-inflammatory drugs and methods and devices for their use

Devices, systems, methods, and compositions are provided herein including a composition for coupling to a surface of an implantable article, said composition comprising: an anti-coagulant comprising a direct factor Xa inhibitor and at least one of (a) an anti-platelet drug, (b) anti-coagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.
Owner:ELIXIR MEDICAL CORP

Preparation method of quality control product for urine visible component analysis

The invention discloses a preparation method of a quality control product for urine visible component analysis, which comprises the following steps: taking a certain amount of phosphate buffer solution, osmotic pressure regulator, anticoagulant and preservative, and preparing into preserving fluid; the preservation solution and an aldehyde reagent are uniformly mixed in proportion to prepare a stationary solution, and the concentration of the aldehyde reagent is 0.50-4.00% (w%); carrying out centrifugal treatment on the biological source cells by utilizing the preserving fluid; adding a stationary liquid into the centrifuged biological source cells, and standing; and cleaning the fixed biological source cells by using the preserving fluid, and resuspending to obtain the quality control product. According to the quality control material for urine visible component analysis, provided by the invention, the main raw materials are pig source cells, and compared with other patents, the human source is wide in source, and the biological safety can be better improved; the quality control product provided by the invention is simple in preparation process and easy to produce, greatly reduces the reagent concentration, shortens the fixing time, is good in cell morphology and smooth in cell membrane when being observed under a microscope, and is beneficial to environmental protection and cost reduction.
Owner:JILIN GETEIN BIOTECH CO LTD

Compositions and methods for evaluating anticoagulant therapeutic efficacy

ActiveUS12421298B2Disease diagnosisBiological testingEfficacyFibrin deposition
In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and / or deposited fibrin.
Owner:THE SCRIPPS RES INST

Microfluidic chip-based, universal coagulation assay

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.
Owner:PEROSPHERE TECHNOLOGIES INC

A modified polyimide hollow fiber membrane and its application

The present invention discloses a modified polyimide hollow fiber membrane. The hollow fiber membrane comprises a polysulfone / polyethersulfone matrix component and a modified polyimide hydrophobic polymer containing 30% to 100% of the matrix component by weight. The modified polyimide hydrophobic polymer is prepared by mixing water, a strongly polar solvent, an alkaline catalyst, and a polyimide resin at 80 to 120°C for a partial hydrolysis reaction for 5 to 10 hours. After the solution is cooled, the pH is adjusted to 1 to 3 to remove water. A polyamine is first added and stirred for 2 to 4 hours. A carboxyl-containing anticoagulant is then added and a grafting reaction is carried out for 12 to 48 hours to obtain the modified polyimide hydrophobic polymer. The hollow fiber membrane prepared by the present invention has a good ultrafiltration coefficient, significantly improved hydrophilicity, effectively reduces the deposition of prothrombin and fibrin, and significantly improves the anticoagulant effect, making it suitable for use as a blood purification material.
Owner:GUANGZHOU KONCEN BIOSCI

Factor xa reagent

To provide a factor Xa reagent.SOLUTION: Exemplary compositions include Factor Xa, a substrate, one or more guanidine derivatives, and in some cases heparin. An exemplary method of detecting an anticoagulant in a sample includes combining or contacting a composition with a sample and measuring factor Xa activity based on substrate status. The composition modulates the activity of factor Xa in the sample, and the modulation includes a reduction in the rate of clotting of the sample caused by factor Xa. The presence of an anticoagulant is based on the activity of factor Xa.SELECTED DRAWING: None
Owner:INSTRUMENTATION LABORATORY COMPANY

Lymphatic-targeted anticoagulants for the prevention of lymphatic thrombosis

Novel methods, compositions and kits for using lymphatic targeting anti-thrombosis (LTAT) molecules are provided herein. The LTAT molecules can be used to treat or prevent lymphatic thrombosis resulting particularly from infection or inflammation in the intestine.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA